Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017.
At Least 10 New Cellular Therapies Will Launch Over Next Decade, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cellular therapies drug...

Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States.
Over 70 Percent of Hospitals Have a Closed Formulary for Antibiotics, According To New Data from Arlington Medical Resources MALVERN, Pa., Dec. 2 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that Ortho-McNeil-Janssen Pharmaceuticals' Levaquin...

Kaiser Permanente's David Sacks, MD Receives the Norbert Freinkel Lectureship.
HEALTH AND BEAUTY CLOSE-UP-2 December 2008-Kaiser Permanente's David Sacks, MD Receives the Norbert Freinkel Lectureship(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com According to the American Diabetes Association (ADA), if current trends continue, one in three Americans - and one in two minorities - born in 2000 will develop diabetes...

NCCN Awarded $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer.
HEALTH AND BEAUTY CLOSE-UP-29 November 2008-NCCN Awarded $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com The National Comprehensive Cancer Network (NCCN), Bristol-Myers Squibb Company and ImClone Systems Inc. have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in bladder...

Decision Biomarkers Inc Announces Formation of Scientific Advisory Board.
WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Biomarkers Inc, a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the formation of a Scientific Advisory Board consisting of internationally renowned scientists and physicians at the forefront of biomarker and clinical research. The Scientific Advisory...

IsoRay Names New VP of Business Development in Charge of Sales.
HEALTH AND BEAUTY CLOSE-UP-29 November 2008-IsoRay Names New VP of Business Development in Charge of Sales(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com IsoRay Inc., a medical isotope company focusing on the treatment of prostate and other malignant disease through use of its proprietary radioisotope technology, announced that its operating...

PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
Study Expanded to 406 Subjects FRANKLIN, Mass., Nov. 26 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF) announced today that it has received full approval from the U.S. Food and Drug Administration (FDA) for its U.S. pivotal trial to study the effectiveness of the Company's RenalGuard...

The effects of chicken leg bone extract on antioxidative properties under different heating condition.
ABSTRACT : The aim of this study was to extract chicken leg bone, which is a by-product of industrial poultry processing, using different heating temperatures (80, 90 and 100[degrees]C) and durations (5, 10 and 15 min). The pH value, soluble protein content, peptide content and antioxidative properties, including superoxide...

Siemens Unveils MR Oncology Applications and Dedicated Breast Scanner at RSNA 2008.
MAGNETOM Espree - Pink. Excellence in MR Breast Care CHICAGO, Nov. 30 /PRNewswire-FirstCall/ -- Siemens Healthcare (http://www.siemens.com/healthcare) redefines Magnetic Resonance (MR) in Oncology with Tim(TM) (Total imaging matrix) technology at the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from November...

Nymox Releases Results of Its 59 Week Study of Drug for Enlarged Prostate.
HEALTH AND BEAUTY CLOSE-UP-18 November 2008-Nymox Releases Results of Its 59 Week Study of Drug for Enlarged Prostate(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Nymox Pharmaceutical announced positive new results from the Company's most recent study of NX-1207, its drug in development for benign prostatic hyperplasia (BPH). ...